Follow
Akshay Binayke
Title
Cited by
Cited by
Year
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and a …
R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ...
The Lancet Infectious Diseases 22 (4), 473-482, 2022
942022
Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection
ZA Rizvi, R Dalal, S Sadhu, A Binayke, J Dandotiya, Y Kumar, ...
Elife 11, e73522, 2022
512022
Awakening the “guardian of genome”: reactivation of mutant p53
A Binayke, S Mishra, P Suman, S Das, H Chander
Cancer chemotherapy and pharmacology 83, 1-15, 2019
452019
SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
R Thiruvengadam, A Binayke, A Awasthi
The Lancet Infectious Diseases 22 (3), 301-302, 2022
252022
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 …
S Thuluva, V Paradkar, SR Gunneri, V Yerroju, RR Mogulla, PV Suneetha, ...
Vaccine 40 (49), 7130-7140, 2022
242022
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized …
S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, PV Suneetha, ...
Human Vaccines & Immunotherapeutics 19 (1), 2203632, 2023
19*2023
Analysis of diversity of actinomycetes from arid and saline soils at Rajasthan, India
A Binayke, S Ghorbel, N Hmidet, A Raut, A Gunjal, A Uzgare, N Patil, ...
Environmental Sustainability 1 (1), 61-70, 2018
152018
Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B· 1· 617· 2 delta variant …
R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ...
132021
Proinflammatory innate cytokines and distinct metabolomic signatures shape the T cell response in active COVID-19
A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, MR Tripathy, ...
Vaccines 10 (10), 1762, 2022
10*2022
IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation
S Sadhu, R Dalal, J Dandotiya, A Binayke, V Singh, MR Tripathy, V Das, ...
Nature Communications 14 (1), 4060, 2023
92023
SARS-CoV-2 and its variants, but not Omicron, induces thymic atrophy and impaired T cell development
ZA Rizvi, S Sadhu, J Dandotiya, A Binyka, P Sharma, V Singh, V Das, ...
bioRxiv, 2022.04. 07.487556, 2022
42022
Cell-Mediated Immunity (CMI) for SARS-CoV-2 Infection Among the General Population of North India: A Cross-Sectional Analysis From a Sub-sample of a Large Sero-Epidemiological …
P Misra, PK Garg, A Awasthi, S Kant, SK Rai, M Ahmad, R Guleria, ...
Cureus 15 (11), 2023
22023
Antiviral activity of the human endogenous retrovirus‐R envelope protein against SARS‐CoV‐2
S Ansari, N Gupta, R Verma, ON Singh, J Gupta, A Kumar, MK Yadav, ...
EMBO reports 24 (7), e55900, 2023
22023
SARS‐CoV‐2 infection induces thymic atrophy mediated by IFN‐γ in hACE2 transgenic mice
ZA Rizvi, S Sadhu, J Dandotiya, P Sharma, A Binayke, V Singh, V Das, ...
European Journal of Immunology, 2350624, 2024
2024
Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study
A Sasi, J Dandotiya, J Kaushal, S Ganguly, A Binayke, KM Ambika, ...
Vaccine 42 (10), 2722-2728, 2024
2024
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation
A Binayke, A Zaheer, S Vishwakarma, S Singh, P Sharma, ...
npj Vaccines 9 (1), 3, 2024
2024
Case report: Correlation of immune profiling and exceptional response to immune checkpoint inhibitor in a patient with head and neck cancer
K Jain, DK Rathore, S Ganguly, A Binayke, NK Ganguly, A Awasthi, ...
Journal of Cancer Research and Therapeutics, 2023
2023
Artemotil mediates protection in experimental colitis through the induction of Type 1 regulatory T cells
U Madan, B Verma, A Binayke, A Awasthi
The Journal of Immunology 210 (1_Supplement), 238.05-238.05, 2023
2023
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or …
S Thuluva, V Paradkar, S Gunneri, V Yerroju, R Mogulla, PV Suneetha, ...
medRxiv, 2022.12. 29.22284049, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–19